Research programme: neurological disorder therapeutics - Neurogene
Latest Information Update: 05 Jul 2021
At a glance
- Originator Neurogene Inc
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 24 Jun 2021 Preclinical trials in Neurological disorders in USA (Parenteral) (Neurogene Inc pipeline, June 2021)
- 13 Jan 2021 Research programme: neurological disorder therapeutics - Neurogene is available for licensing as of 13 Jan 2021. https://www.neurogene.com/
- 13 Jan 2021 Early research in Neurological disorders in USA (Parenteral) (Neurogene Inc pipeline, January 2021)